Phase II Trial of Topotecan and Cisplatin in Persistent or Recurrent Squamous and Nonsquamous Carcinomas of the Cervix

This publication has 19 references indexed in Scilit:

• Intent-to-treat analysis of stage Ib and IIa cervical cancer in the United States: radiotherapy or surgery 1988–1995
  Obstetrics & Gynecology, 2001
• Cancer Statistics, 2001
  CA: A Cancer Journal for Clinicians, 2001
• Topotecan Has Substantial Antitumor Activity as First-Line Salvage Therapy in Platinum-Sensitive Epithelial Ovarian Carcinoma: A Gynecologic Oncology Group Study
  Journal of Clinical Oncology, 2000
• Cancer statistics, 1999
  CA: A Cancer Journal for Clinicians, 1999
• Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
  Journal of Clinical Oncology, 1998
• In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems
  Cancer Chemotherapy and Pharmacology, 1998
• Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro
  Cancer Chemotherapy and Pharmacology, 1998
• Topotecan in Platinum- and Paclitaxel-Resistant Ovarian Cancer
  Gynecologic Oncology, 1997
• Computerized Quantitation of Synergism and Antagonism of Taxol, Topotecan, and Cisplatin Against Human Teratocarcinoma Cell Growth: a Rational Approach to Clinical Protocol Design
  JNCI Journal of the National Cancer Institute, 1994
• Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study.
  Journal of Clinical Oncology, 1985